1. Home
  2. Live Updates
  3. Sophia humphreys

Live Breaking News & Updates on Sophia humphreys

Stay informed with the latest breaking news from Sophia humphreys on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Sophia humphreys and stay connected to the pulse of your community

Dr Sohpia Humphreys Explains Health Equity in Metabolic Health Care

With the high burden of metabolic disease increasing in the US, Sophia Humphreys, PharmD, Sutter Health, explains how this impacts health equity.

San-francisco , California , United-states , American , Sophia-humphreys , Clinical-services , Sutter-health , American-journal , Formulary-management , Diabetes , Pharmacy , Health-equity

Strategies to Increase Adalimumab Biosimilar Uptake in Clinical Practice

A clinical pharmacist and specialists in rheumatology, dermatology, and gastrointestinal disease share strategies in how to increase the uptake of adalimumab biosimilar among providers.

Kostas-botsoglou , Sophia-humphreys , Jamiet-brogan , Jordan-axelrad , Peter-lio , Adalimumab , Biosimilars , Uptake-of-adalimumab , Strategies ,

Selecting Between Adalimumab Biosimilars for Your Patients

Providers in rheumatology, dermatology and gastrointestinal disease talk about how they are selecting between the various adalimumab biosimilars available for their patients.

Kostas-botsoglou , Sophia-humphreys , Jamiet-brogan , Jordan-axelrad , Peter-lio , Adalimumab , Biosimilars , Treatment-selection ,

Impact of the Launch of Adalimumab Biosimilars in Different Clinical and Pharmacy Settings

Experts talk about the impact of the launch of adalimumab biosimilar on their clinical practices and pharmacy.

Sophia-humphreys , Kostas-botsoglou , Jamiet-brogan , Jordan-axelrad , Peter-lio , Biosimilars , Adalimumab , Gastro , Rheumatoid-arthritis , Ra , Dermatology

The Role of Pharmacy Benefit Managers and Payers in Accessing Adalimumab Biosimilars

A clinical pharmacist discusses the role of pharmacy benefit managers and payers in accessibility of adalimumab biosimilars.

United-states , New-york , Sophia-humphreys , Kostas-botsoglou , Jamiet-brogan , Jordan-axelrad , Peter-lio , Biosimilars , Pharmacy-benefit-managers , Payers , Adalimumab , Pbms

The Safety and Efficacy of Adalimumab Biosimilars in Inflammatory Diseases

Specialists in rheumatology, dermatology and gastrointestinal disease discuss clinical trials that have shown safety and efficacy of adalimumab biosimilars in inflammatory diseases.

United-states , Kostas-botsoglou , Jamiet-brogan , Sophia-humphreys , Jordan-axelrad , Peter-lio ,

The Pharmacological Aspects of Adalimumab Biosimilars

A clinical pharmacist reviews the various pharmacological aspects of the available adalimumab biosimilars.

Sophia-humphreys , Kostas-botsoglou , Jamiet-brogan , Jordan-axelrad , Peter-lio , Adalimumab , Biosimilars , Citrate-free ,

The Need for Biosimilars in Inflammatory Diseases and Regulatory Requirements for Approval

Drs Lio, Botsoglou, and Axelrad discuss the need for biosimilars in inflammatory diseases, and clinical pharmacist Dr Humphreys reviews the regulatory requirements for biosimilars to receive FDA approval.

Sophia-humphreys , Jamiet-brogan , Kostas-botsoglou , Sutter-health , Jordan-axelrad , Peter-lio , Biologic-price-competition , Innovation-act , Biosimilars , Inflammatory-disease , Regulatory-requirements-for-approval , Bpcia

An Overview of Adalimumab Biosimilars

Clinicians and a pharmacist provide an overview of the emerging adalimumab biosimilars in the recent years.

Jamiet-brogan , Kostas-botsoglou , Sophia-humphreys , Jordan-axelrad , Peter-lio ,

Fentanyl Is Showing Up in Party Pills: What to Know to Stay Safe

"Fentapills” are indistinguishable from the legit Rx drugs they’re pretending to be—like Adderall, Xanax, Percocet, or oxycodone—and they could be fatal.

Texas , United-states , Lemrey-al-carter , Sophia-humphreys , Tiffany-iler , Nabarun-dasgupta , Darcy-michero , Jessica-lopez , Maggie-luna , Nora-volkow , Centers-for-disease , National-institute-on-drug-abuse